Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis

Elisa Ferraris, Pamela Di Cesare, Angioletta Lasagna, Chiara Paglino, Ilaria Imarisio, Camillo Porta

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Patients with renal cell carcinoma (RCC) may exhibit renal impairment as a more or less direct consequence of their primary disease. Renal impairment may become a severe complication and alter the normal pharmacokinetic and pharmacodynamic behavior of treatment drugs, thus increasing the risk of side effects. We will discuss the cases of two advanced RCC patients with end-stage renal impairment submitted to dialysis who were treated with sorafenib tosylate in our center. Our experience confirms the scarce literature data available so far that indicate that sorafenib can be used in patients undergoing dialysis. Dialysis cannot be considered per se a contraindication to sorafenib therapy, which can be effective. However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions.

Original languageEnglish
Pages (from-to)542-544
Number of pages3
JournalTumori
Volume95
Issue number4
Publication statusPublished - 2009

Fingerprint

Renal Cell Carcinoma
Renal Dialysis
Kidney
Dialysis
Pharmacokinetics
sorafenib
Therapeutics
Pharmaceutical Preparations

Keywords

  • Dialysis
  • End-stage renal impairment
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. / Ferraris, Elisa; Di Cesare, Pamela; Lasagna, Angioletta; Paglino, Chiara; Imarisio, Ilaria; Porta, Camillo.

In: Tumori, Vol. 95, No. 4, 2009, p. 542-544.

Research output: Contribution to journalArticle

Ferraris, Elisa ; Di Cesare, Pamela ; Lasagna, Angioletta ; Paglino, Chiara ; Imarisio, Ilaria ; Porta, Camillo. / Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. In: Tumori. 2009 ; Vol. 95, No. 4. pp. 542-544.
@article{115c7a8f28fe45c58423496f592f60ba,
title = "Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis",
abstract = "Patients with renal cell carcinoma (RCC) may exhibit renal impairment as a more or less direct consequence of their primary disease. Renal impairment may become a severe complication and alter the normal pharmacokinetic and pharmacodynamic behavior of treatment drugs, thus increasing the risk of side effects. We will discuss the cases of two advanced RCC patients with end-stage renal impairment submitted to dialysis who were treated with sorafenib tosylate in our center. Our experience confirms the scarce literature data available so far that indicate that sorafenib can be used in patients undergoing dialysis. Dialysis cannot be considered per se a contraindication to sorafenib therapy, which can be effective. However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions.",
keywords = "Dialysis, End-stage renal impairment, Sorafenib",
author = "Elisa Ferraris and {Di Cesare}, Pamela and Angioletta Lasagna and Chiara Paglino and Ilaria Imarisio and Camillo Porta",
year = "2009",
language = "English",
volume = "95",
pages = "542--544",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis

AU - Ferraris, Elisa

AU - Di Cesare, Pamela

AU - Lasagna, Angioletta

AU - Paglino, Chiara

AU - Imarisio, Ilaria

AU - Porta, Camillo

PY - 2009

Y1 - 2009

N2 - Patients with renal cell carcinoma (RCC) may exhibit renal impairment as a more or less direct consequence of their primary disease. Renal impairment may become a severe complication and alter the normal pharmacokinetic and pharmacodynamic behavior of treatment drugs, thus increasing the risk of side effects. We will discuss the cases of two advanced RCC patients with end-stage renal impairment submitted to dialysis who were treated with sorafenib tosylate in our center. Our experience confirms the scarce literature data available so far that indicate that sorafenib can be used in patients undergoing dialysis. Dialysis cannot be considered per se a contraindication to sorafenib therapy, which can be effective. However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions.

AB - Patients with renal cell carcinoma (RCC) may exhibit renal impairment as a more or less direct consequence of their primary disease. Renal impairment may become a severe complication and alter the normal pharmacokinetic and pharmacodynamic behavior of treatment drugs, thus increasing the risk of side effects. We will discuss the cases of two advanced RCC patients with end-stage renal impairment submitted to dialysis who were treated with sorafenib tosylate in our center. Our experience confirms the scarce literature data available so far that indicate that sorafenib can be used in patients undergoing dialysis. Dialysis cannot be considered per se a contraindication to sorafenib therapy, which can be effective. However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions.

KW - Dialysis

KW - End-stage renal impairment

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=70350076873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350076873&partnerID=8YFLogxK

M3 - Article

C2 - 19856673

AN - SCOPUS:70350076873

VL - 95

SP - 542

EP - 544

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -